Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

ANGN

Angion Biomedica (ANGN)

Angion Biomedica Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ANGN
DateHeureSourceTitreSymboleSociété
29/04/202413h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
05/04/202422h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGNAngion Biomedica Corporation
29/03/202420h28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANGNAngion Biomedica Corporation
29/03/202420h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANGNAngion Biomedica Corporation
29/03/202418h58Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANGNAngion Biomedica Corporation
20/03/202421h37Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
20/03/202421h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANGNAngion Biomedica Corporation
05/01/202422h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ANGNAngion Biomedica Corporation
13/11/202314h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGNAngion Biomedica Corporation
12/08/202303h13Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
07/07/202315h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGNAngion Biomedica Corporation
14/06/202322h05Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ANGNAngion Biomedica Corporation
14/06/202320h43Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ANGNAngion Biomedica Corporation
12/06/202323h13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANGNAngion Biomedica Corporation
05/06/202323h26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ANGNAngion Biomedica Corporation
05/06/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANGNAngion Biomedica Corporation
01/06/202314h00GlobeNewswire Inc.Angion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitNASDAQ:ANGNAngion Biomedica Corporation
24/05/202312h01Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ANGNAngion Biomedica Corporation
10/05/202322h14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANGNAngion Biomedica Corporation
28/04/202322h46Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ANGNAngion Biomedica Corporation
28/04/202322h14Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ANGNAngion Biomedica Corporation
17/03/202321h26Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ANGNAngion Biomedica Corporation
14/02/202322h41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ANGNAngion Biomedica Corporation
17/01/202311h00GlobeNewswire Inc.Elicio Therapeutics and Angion Enter into Definitive Merger AgreementNASDAQ:ANGNAngion Biomedica Corporation
22/12/202203h50GlobeNewswire Inc.Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:ANGNAngion Biomedica Corporation
15/08/202222h05GlobeNewswire Inc.Angion Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:ANGNAngion Biomedica Corporation
26/07/202212h17TipRanksH.C. Wainwright Reiterates Their Hold Rating on Angion Biomedica (ANGN)NASDAQ:ANGNAngion Biomedica Corporation
25/07/202222h30GlobeNewswire Inc.Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder ValueNASDAQ:ANGNAngion Biomedica Corporation
29/06/202222h05GlobeNewswire Inc.Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney DiseaseNASDAQ:ANGNAngion Biomedica Corporation
27/05/202222h43Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ANGNAngion Biomedica Corporation
 Showing the most relevant articles for your search:NASDAQ:ANGN